Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Diagnosis, Treatment and Comorbidities of Ankylosing Spondylitis and Spondyloarthritis
share announcement

Clinical Diagnosis, Treatment and Comorbidities of Ankylosing Spondylitis and Spondyloarthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 10 July 2024 | Viewed by 557

Special Issue Editors

Prof. Dr. Abdulla Watad

E-Mail Website
Guest Editor
Department of Medicine B, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan 5262100, Israel
Interests: comorbidities of ankylosing spondylitis; early diagnosis of ankylosing spondylitis; new bone formation; prevention of psoriatic arthritis; enthesitis and enthesopathy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Merav Lidar

E-Mail Website
Guest Editor
Rheumatology Unit, Sheba Medical Center, Tel-Hashomer, Ramat Gan 5262100, Israel
Interests: imaging in spondyloarthropathies; pregnancy issues in spondyloarthropathies

Special Issue Information

Dear Colleagues,

The Special Issue "Clinical Diagnosis, Treatment and Comorbidities of Ankylosing Spondylitis and Spondyloarthritis" delves into pivotal facets surrounding ankylosing spondylitis (AS), expertly curated and edited by distinguished specialists. Focusing on early diagnosis, the issue offers insights into the challenge of identifying AS in its initial stages and the impact on disease progression. Delving deeper into the pathology, it explores the intricate role of enthesitis and enthesopathy, unravelling their significance in disease development. The issue emphasises the prevention of psoriatic arthritis, aiming to elucidate novel preventive measures and therapeutic strategies. Moreover, it sheds light on new bone formation, exploring innovative approaches to inhibit and manage this detrimental aspect of this disease. Addressing the multifaceted nature of AS, we aspire to provide a comprehensive understanding of associated comorbidities, offering clinicians and researchers a deeper understanding of this complex rheumatic condition.

Prof. Dr. Abdulla Watad
Prof. Dr. Merav Lidar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ankylosing spondylitis
  • comorbidities of spondyloarthritis
  • early diagnosis
  • enthesitis and enthesopathy
  • prevention of spondyloarthritis
  • new bone formation
  • ankylosing spondylitis management
  • ankylosing spondylitis from big data
  • immunopathogenesis of SpA

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 344 KiB  
Article
Increased Risk for Pulmonary Embolism among Patients with Ankylosing Spondylitis—Results from a Large Database Analysis
by Omer Gendelman, Neta Simon, Niv Ben-Shabat, Yonatan Shneor Patt, Dennis McGonagle, Arnon Dov Cohen, Howard Amital and Abdulla Watad
J. Clin. Med. 2024, 13(10), 2790; https://doi.org/10.3390/jcm13102790 - 9 May 2024
Viewed by 411
Abstract
Background: Axial spondyloarthropathy(AS) is a chronic inflammatory disease primarily affecting the axial skeleton, often characterized by sacroiliitis. While pulmonary embolism (PE), a potentially lethal condition, has been linked to several autoimmune diseases, limited data exist regarding PE risk among patients with AS. Methods: [...] Read more.
Background: Axial spondyloarthropathy(AS) is a chronic inflammatory disease primarily affecting the axial skeleton, often characterized by sacroiliitis. While pulmonary embolism (PE), a potentially lethal condition, has been linked to several autoimmune diseases, limited data exist regarding PE risk among patients with AS. Methods: This retrospective cohort study utilized the Clalit Healthcare Services (CHS) database, including 5825 patients with AS and 28,356 matched controls. Follow-up began at the date of first AS diagnosis for patients and at the matched patient’s diagnosis date for controls and continued until PE diagnosis, death, or study end date. Results: Prevalence of PE before AS diagnosis in patients compared to controls was 0.4% vs. 0.2% (p < 0.01). The incidence rate of PE was 11.6 per 10,000 person-years for patients with AS and 6.8 per 10,000 person-years for controls. The adjusted hazard ratio (HR) for PE in patients with AS was 1.70 (p < 0.001). Subgroup analysis demonstrated excess risk for PE in patients with AS regardless of gender and age, with variations among AS treatment categories. Discussion: Our findings highlight a significant association between AS and PE, indicating an increased risk in patients with AS independent of age and sex and suggests a subclinical level of inflammation. Preliminary results suggest a protective role of immunosuppressing drugs. Further research into the impact of treatment strategies should be conducted and could inform clinical management and reduce the life-threatening risk of PE in Patients with AS. Full article
(This article belongs to the Special Issue Clinical Diagnosis, Treatment and Comorbidities of Ankylosing Spondylitis and Spondyloarthritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop